Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 11/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20415160 | 1.00 | TMEM97 (0.55) | TMEM97SIGMAR1SMN1; SMN2AKR1C3AKR1C2 | |
| Hydrochloric Acid SCHEMBL29073235 | 0.99 | TMEM97 (0.54) | TMEM97SIGMAR1SMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL24495795 | 0.86 | AKR1C1 (0.48) | SMN1; SMN2AKR1C3AKR1C2AKR1C1KDM4E | |
| SCHEMBL29293504 | 0.82 | TMEM97 (0.48) | TMEM97SIGMAR1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL20415173 | 0.79 | KDM4E (0.45) | TMEM97SIGMAR1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL20415155 | 0.79 | KDM4E (0.45) | TMEM97SIGMAR1AKR1C3AKR1C2AKR1C1 | |
| Hydrochloric Acid SCHEMBL20400563 | 0.78 | KDM4E (0.44) | TMEM97SIGMAR1SMN1; SMN2AKR1C3AKR1C2 | |
| Hydrochloric Acid SCHEMBL20401573 | 0.78 | KDM4E (0.44) | TMEM97SIGMAR1SMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL20415153 | 0.77 | TMEM97 (0.47) | TMEM97SIGMAR1AKR1C3AKR1C2AKR1C1 | |
| Hydrochloric Acid SCHEMBL4786199 | 0.76 | TMEM97 (0.64) | TMEM97SIGMAR1SMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397652-A2 | 3-(PHENYL)-2-(AMINOMETHYL)-1-PHENYL-2-PROPEN-1-ONE DERIVATIVES AS INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR FOR TREATING PROSTATE CANCER | The Regents of the University of California (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-110325508-B | Inhibitors of the N-terminal domain of androgen receptor | 加利福尼亚大学董事会 | 2023-06-30 | — | — | CN | disclosed |
| US-20220177418-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | disclosed |
| WO-2020205470-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2018136792-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177418-A1 | INHIBITORS OF THE N-TERMINAL DOMAIN OF THE ANDROGEN RECEPTOR | AR, BRDT, NR5A1 | TMEM97 1389/4885SIGMAR1 1480/4885SMN1; SMN2 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.